Improved prediction of complex diseases by common genetic markers: state of the art and further perspectives

Human Genetics

Volumn 135, Issue 3, 2016, Pages 259-272

  Müller, Bent ^a   Wilcke, Arndt ^a,b   Boulesteix, Anne Laure ^c   Brauer, Jens ^d   Passarge, Eberhard ^e,f   Boltze, Johannes ^a,b,g,h   Kirsten, Holger ^a,b,i  

^a FRAUNHOFER INSTITUTE FOR CELL THERAPY AND IMMUNOLOGY   (Germany)

^b Translational Center for Regenerative Medicine   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d MAX PLANCK INSTITUTE FOR HUMAN COGNITIVE AND BRAIN SCIENCES   (Germany)

^e UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h UNIVERSITY OF LÜBECK   (Germany)

ⁱ UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL RESEARCH; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC MARKER; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEDLINE; METHODOLOGY; PATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; CARDIOVASCULAR DISEASES; GENETICS; GENOTYPING TECHNIQUE; NEOPLASMS;

GENETIC MARKER;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS; GENETIC MARKERS; GENOTYPING TECHNIQUES; HUMANS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT;

EID: 84958767731     PISSN: 03406717     EISSN: 14321203     Source Type: Journal    
DOI: 10.1007/s00439-016-1636-z     Document Type: Review

References (91)

1. Aly M, Wiklund F, Xu J et al (2011) Polygenic risk score improves prostate cancer risk prediction: Results from the Stockholm-1 cohort study. Eur Urol 60:21–28. doi:10.1016/j.eururo.2011.01.017
2. Ankerst DP, Thompson IM (2012) Words of wisdom. Re: Combining 33 genetic variants with prostate-specific antigen for the prediction of prostate cancer: longitudinal study. Eur Urol 62:180. doi:10.1016/j.eururo.2012.04.010
3. Ankerst DP, Boeck A, Freedland SJ et al (2012) Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol 30:181–187. doi:10.1007/s00345-011-0818-5
4. Antman E, Weiss S, Loscalzo J (2012) Systems pharmacology, pharmacogenetics, and clinical trial design in network medicine. Wiley Interdiscip Rev Syst Biol Med 4:367–383. doi:10.1002/wsbm.1173
5. Balkau B, Lange C, Fezeu L et al (2008) Predicting diabetes: clinical, biological, and genetic approaches: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 31:2056–2061. doi:10.2337/dc08-0368
6. Bamber D (1975) The area above the ordinal dominance graph and the area below the receiver operating characteristic graph. J Math Psychol 12:387–415. doi:10.1016/0022-2496(75)90001-2
7. Beaney KE, Cooper JA, Ullah Shahid S et al (2015) Clinical Utility of a Coronary Heart Disease Risk Prediction Gene Score in UK Healthy Middle Aged Men and in the Pakistani Population. PLoS One 10:e0130754. doi:10.1371/journal.pone.0130754
8. Bolton JL, Stewart MCW, Wilson JF et al (2013) Improvement in prediction of coronary heart disease risk over conventional risk factors using SNPs identified in genome-wide association studies. PLoS One 8:e57310. doi:10.1371/journal.pone.0057310
9. Brautbar A, Pompeii LA, Dehghan A et al (2012) A genetic risk score based on direct associations with coronary heart disease improves coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC), but not in the Rotterdam and Framingham Offspring, Studies. Atherosclerosis 223:421–426. doi:10.1016/j.atherosclerosis.2012.05.035
10. Bruzelius M, Bottai M, Sabater-Lleal M et al (2014) Predicting venous thrombosis in women using a combination of genetic markers and clinical risk factors. J Thromb Haemost 53:219–227. doi:10.1111/jth.12808
11. Butoescu V, Ambroise J, Stainier A et al (2014) Does genotyping of risk-associated single nucleotide polymorphisms improve patient selection for prostate biopsy when combined with a prostate cancer risk calculator? Prostate 74:365–371. doi:10.1002/pros.22757
12. Chang J, Huang Y, Wei L et al (2013) Risk prediction of esophageal squamous-cell carcinoma with common genetic variants and lifestyle factors in Chinese population. Carcinogenesis 34:1782–1786. doi:10.1093/carcin/bgt106
13. Cook NR (2007) Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 115:928–935. doi:10.1161/CIRCULATIONAHA.106.672402
14. Cook NR, Paynter NP (2010) Genetics and breast cancer risk prediction–are we there yet? J Natl Cancer Inst 102:1605–1606. doi:10.1093/jnci/djq413
15. Cook NR, Paynter NP (2011) Performance of reclassification statistics in comparing risk prediction models. Biom J 53:237–258. doi:10.1002/bimj.201000078
16. Darabi H, Czene K, Zhao W et al (2012) Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement. Breast Cancer Res 14:R25. doi:10.1186/bcr3110
17. Davies RW, Dandona S, Stewart AFR et al (2010) Improved prediction of cardiovascular disease based on a panel of single nucleotide polymorphisms identified through genome-wide association studies. Circ Cardiovasc Genet 3:468–474. doi:10.1161/CIRCGENETICS.110.946269
18. De Haan HG, Bezemer ID, Doggen CJM et al (2012) Multiple SNP testing improves risk prediction of first venous thrombosis. Blood 120:656–663. doi:10.1182/blood-2011-12-397752
19. De Miguel-Yanes JM, Shrader P, Pencina MJ et al (2011) Genetic risk reclassification for type 2 diabetes by age below or above 50 years using 40 type 2 diabetes risk single nucleotide polymorphisms. Diabetes Care 34:121–125. doi:10.2337/dc10-1265
20. De Vries PS, Kavousi M, Ligthart S et al (2015) Incremental predictive value of 152 single nucleotide polymorphisms in the 10-year risk prediction of incident coronary heart disease: the Rotterdam Study. Int J Epidemiol 44:682–688. doi:10.1093/ije/dyv070
21. Diamandis M, White NMA, Yousef GM (2010) Personalized medicine: marking a new epoch in cancer patient management. Mol Cancer Res 8:1175–1187. doi:10.1158/1541-7786.MCR-10-0264
22. Dite GS, Mahmoodi M, Bickerstaffe A et al (2013) Using SNP genotypes to improve the discrimination of a simple breast cancer risk prediction model. Breast Cancer Res Treat 139:887–896. doi:10.1007/s10549-013-2610-2
23. Dudbridge F (2013) Power and predictive accuracy of polygenic risk scores. PLoS Genet 9:e1003348. doi:10.1371/journal.pgen.1003348
24. Everett BM, Cook NR, Conen D et al (2013) Novel genetic markers improve measures of atrial fibrillation risk prediction. Eur Heart J 34:2243–2251. doi:10.1093/eurheartj/eht033
25. Fang S, Han J, Zhang M et al (2013) Joint effect of multiple common SNPs predicts melanoma susceptibility. PLoS One 8:1–9. doi:10.1371/journal.pone.0085642
26. Ganna A, Magnusson PKE, Pedersen NL et al (2013) Multilocus genetic risk scores for coronary heart disease prediction. Arterioscler Thromb Vasc Biol 33:2267–2272. doi:10.1161/ATVBAHA.113.301218
27. Garcia-Closas M, Couch FJ, Lindstrom S, et al (2013) Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet 45:392–8, 398e1–2. doi: 10.1038/ng.2561
28. Gershon ES, Alliey-Rodriguez N, Liu C (2011) After GWAS: searching for genetic risk for schizophrenia and bipolar disorder. Am J Psychiatry 168:253–256. doi:10.1176/appi.ajp.2010.10091340
29. Ginsburg GS, McCarthy JJ (2001) Personalized medicine: Revolutionizing drug discovery and patient care. Trends Biotechnol 19:491–496
30. Hagemann IS, Cottrell CE, Lockwood CM (2013) Design of targeted, capture-based, next generation sequencing tests for precision cancer therapy. Cancer Genet 206:420–431. doi:10.1016/j.cancergen.2013.11.003
31. Hall TO, Wan JY, Mata IF et al (2013) Risk prediction for complex diseases: application to Parkinson disease. Genet Med 15:361–367. doi:10.1038/gim.2012.109
32. Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29–36
33. Helfand BT, Loeb S, Hu Q et al (2013) Personalized prostate specific antigen testing using genetic variants may reduce unnecessary prostate biopsies. J Urol 189:1697–1701. doi:10.1016/j.juro.2012.12.023
34. Hernesniemi JA, Seppälä I, Lyytikäinen L-P et al (2012) Genetic profiling using genome-wide significant coronary artery disease risk variants does not improve the prediction of subclinical atherosclerosis: the Cardiovascular Risk in Young Finns Study, the Bogalusa Heart Study and the Health 2000 Survey—a meta-analysis of three independent studies. PLoS One 7:e28931. doi:10.1371/journal.pone.0028931
35. Horne BD, Anderson JL, Carlquist JF et al (2005) Generating genetic risk scores from intermediate phenotypes for use in association studies of clinically significant endpoints. Ann Hum Genet 69:176–186. doi:10.1046/j.1529-8817.2005.00155.x
36. Hughes MF, Saarela O, Stritzke J et al (2012) Genetic markers enhance coronary risk prediction in men: the MORGAM prospective cohorts. PLoS One 7:e40922. doi:10.1371/journal.pone.0040922
37. Humphries SE, Cooper JA, Talmud PJ, Miller GJ (2007) Candidate gene genotypes, along with conventional risk factor assessment, improve estimation of coronary heart disease risk in healthy UK men. Clin Chem 53:8–16. doi:10.1373/clinchem.2006.074591
38. Ibrahim-Verbaas CA, Fornage M, Bis JC et al (2014) Predicting stroke through genetic risk functions: the CHARGE Risk Score Project. Stroke 45:403–412. doi:10.1161/STROKEAHA.113.003044
39. Insel TR, Cuthbert BN (2009) Endophenotypes: bridging genomic complexity and disorder heterogeneity. Biol Psychiatry 66:988–989. doi:10.1016/j.biopsych.2009.10.008
40. Isaacs A, Willems SM, Bos D et al (2013) Risk scores of common genetic variants for lipid levels influence atherosclerosis and incident coronary heart disease. Arterioscler Thromb Vasc Biol 33:2233–2239. doi:10.1161/ATVBAHA.113.301236
41. Janssens ACJW, Ioannidis JPA, Van Duijn CM et al (2011) Strengthening the reporting of genetic risk prediction studies: The GRIPS statement. Eur J Clin Invest 41:1004–1009. doi:10.1111/j.1365-2362.2011.02494.x
42. Johansson M, Holmström B, Hinchliffe SR et al (2012) Combining 33 genetic variants with prostate-specific antigen for prediction of prostate cancer: longitudinal study. Int J Cancer 130:129–137. doi:10.1002/ijc.25986
43. Kader AK, Sun J, Reck BH et al (2012) Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: Findings from the REDUCE trial. Eur Urol 62:953–961. doi:10.1016/j.eururo.2012.05.006
44. Kathiresan S, Melander O, Anevski D et al (2008) Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 358:1240–1249
45. Klein RJ, Hallden C, Gupta A et al (2012) Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men. Eur Urol 61:471–477. doi:10.1016/j.eururo.2011.10.047
46. Kooperberg C, LeBlanc M, Obenchain V (2010) Risk prediction using genome-wide association studies. Genet Epidemiol 34:643–652. doi:10.1002/gepi.20509
47. Kruppa J, Ziegler A, König IR (2012) Risk estimation and risk prediction using machine-learning methods. Hum Genet 131:1639–1654. doi:10.1007/s00439-012-1194-y
48. Lander ES, Schork NJ (1994) Genetic dissection of complex traits. Science 265:2037–2048
49. Lemeshow S, Hosmer DW (1982) A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 115:92–106
50. Lin X, Song K, Lim N et al (2009) Risk prediction of prevalent diabetes in a Swiss population using a weighted genetic score—the CoLaus Study. Diabetologia 52:600–608. doi:10.1007/s00125-008-1254-y
51. Lindström S, Schumacher FR, Cox D et al (2012) Common genetic variants in prostate cancer risk prediction-results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev 21:437–444. doi:10.1158/1055-9965.EPI-11-1038
52. Lluis-Ganella C, Subirana I, Lucas G et al (2012) Assessment of the value of a genetic risk score in improving the estimation of coronary risk. Atherosclerosis 222:456–463. doi:10.1016/j.atherosclerosis.2012.03.024
53. Lyssenko V, Jonsson A, Almgren P et al (2008) Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 359:2220–2232. doi:10.1056/NEJMoa0801869
54. Mealiffe ME, Stokowski RP, Rhees BK et al (2010) Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information. J Natl Cancer Inst 102:1618–1627. doi:10.1093/jnci/djq388
55. Meigs JB, Shrader P, Sullivan LM et al (2008) Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 359:2208–2219. doi:10.1056/NEJMoa0804742
56. Morrison AC, Bare LA, Chambless LE et al (2007) Prediction of coronary heart disease risk using a genetic risk score: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 166:28–35. doi:10.1093/aje/kwm060
57. Mühlenbruch K, Jeppesen C, Joost H-G et al (2013) The value of genetic information for diabetes risk prediction—differences according to sex, age, family history and obesity. PLoS One 8:e64307. doi:10.1371/journal.pone.0064307
58. Nam RK, Zhang WW, Trachtenberg J et al (2009) Utility of incorporating genetic variants for the early detection of prostate cancer. Clin Cancer Res 15:1787–1793. doi:10.1158/1078-0432.ccr-08-1593
59. Paynter NP, Chasman DI, Buring JE et al (2009) Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med 150:65–72. doi:10.7326/0003-4819-150-2-200901200-00003
60. Paynter NP, Chasman DI, Paré G et al (2010) Association between a literature-based genetic risk score and cardiovascular events in women. JAMA 303:631–637. doi:10.1001/jama.2010.119
61. Pencina MJ, D’Agostino RB, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27:157–172. doi:10.1002/sim.2929(discussion 207–12)
62. Pencina MJ, D’Agostino RB, Vasan RS (2010) Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med 48:1703–1711. doi:10.1515/CCLM.2010.340
63. Pepe MS (2011) Problems with risk reclassification methods for evaluating prediction models. Am J Epidemiol 173:1327–1335. doi:10.1093/aje/kwr013
64. Pepe M, Janes H (2013) Methods for evaluating prediction performance of biomarkers and tests. In: Lee M-LT, Gail M, Pfeiffer R et al (eds) Risk Assessment and Evaluation of Predictions SE, vol 7. Springer New York, pp 107–142
65. Peterson TA, Doughty E, Kann MG (2013) Towards precision medicine: advances in computational approaches for the analysis of human variants. J Mol Biol 425:4047–4063. doi:10.1016/j.jmb.2013.08.008
66. Previtali E, Bucciarelli P, Passamonti SM, Martinelli I (2011) Risk factors for venous and arterial thrombosis. Blood Transfus 9:120–138. doi:10.2450/2010.0066-10
67. Rembold CM (1998) Number needed to screen: development of a statistic for disease screening. BMJ 317:307–312. doi:10.1136/bmj.317.7154.307
68. Ripatti S, Tikkanen E, Orho-Melander M et al (2010) A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet 376:1393–1400. doi:10.1016/S0140-6736(10)61267-6
69. Salinas CA, Koopmeiners JS, Kwon EM et al (2009) Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate 69:363–372. doi:10.1002/pros.20887
70. Schulze MB, Weikert C, Pischon T et al (2009) Use of multiple metabolic and genetic markers to improve the prediction of type 2 diabetes: the EPIC-Potsdam Study. Diabetes Care 32:2116–2119. doi:10.2337/dc09-0197
71. Siontis GCM, Tzoulaki I, Siontis KC, Ioannidis JPA (2012) Comparisons of established risk prediction models for cardiovascular disease: systematic review. BMJ 344:e3318
72. Steyerberg EW, Vickers AJ, Cook NR et al (2010) Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 21:128–138. doi:10.1097/EDE.0b013e3181c30fb2
73. Stranger BE, Stahl EA, Raj T (2011) Progress and promise of genome-wide association studies for human complex trait genetics. Genetics 187:367–383. doi:10.1534/genetics.110.120907
74. Tada H, Shiffman D, Smith JG et al (2014) Twelve-single nucleotide polymorphism genetic risk score identifies individuals at increased risk for future atrial fibrillation and stroke. Stroke 45:2856–2862. doi:10.1161/STROKEAHA.114.006072
75. Talmud PJ, Hingorani AD, Cooper JA et al (2010) Utility of genetic and non-genetic risk factors in prediction of type 2 diabetes: Whitehall II prospective cohort study. BMJ 340:b4838
76. Tam CHT, Ho JSK, Wang Y et al (2013) Use of net reclassification improvement (NRI) method confirms the utility of combined genetic risk score to predict type 2 diabetes. PLoS One. doi:10.1371/journal.pone.0083093
77. Thanassoulis G, Vasan RS (2010) Genetic cardiovascular risk prediction: will we get there? Circulation 122:2323–2334. doi:10.1161/CIRCULATIONAHA.109.909309
78. Tikkanen E, Havulinna AS, Palotie A et al (2013) Genetic risk prediction and a 2-stage risk screening strategy for coronary heart disease. Arterioscler Thromb Vasc Biol 33:2261–2266. doi:10.1161/ATVBAHA.112.301120
79. Tzoulaki I, Liberopoulos G, Ioannidis JPA (2009) Assessment of claims of improved prediction beyond the Framingham risk score. JAMA 302:2345–2352. doi:10.1001/jama.2009.1757
80. Vachon CM, Pankratz VS, Scott CG et al (2015) The contributions of breast density and common genetic variation to breast cancer risk. JNCI J Natl Cancer Inst 107:dju397. doi:10.1093/jnci/dju397
81. Van Hoek M, Dehghan A, Witteman JCM et al (2008) Predicting type 2 diabetes based on polymorphisms from genome-wide association studies: a population-based study. Diabetes 57:3122–3128. doi:10.2337/db08-0425
82. Vassy JL, Meigs JB (2012) Is genetic testing useful to predict type 2 diabetes? Best Pract Res Clin Endocrinol Metab 26:189–201. doi:10.1016/j.beem.2011.09.002
83. Vassy JL, Dasmahapatra P, Meigs JB et al (2012a) Genotype prediction of adult type 2 diabetes from adolescence in a multiracial population. Pediatrics 130:e1235–e1242. doi:10.1542/peds.2012-1132
84. Vassy JL, Durant NH, Kabagambe EK et al (2012b) A genotype risk score predicts type 2 diabetes from young adulthood: the CARDIA study. Diabetologia 55:2604–2612. doi:10.1007/s00125-012-2637-7
85. Vassy JL, Hivert M-F, Porneala B et al (2014) Polygenic type 2 diabetes prediction at the limit of common variant detection. Diabetes 63:2172–2182. doi:10.2337/db13-1663
86. Wacholder S, Hartge P, Prentice R et al (2010) Performance of common genetic variants in breast-cancer risk models. N Engl J Med 362:986–993. doi:10.1056/NEJMoa0907727.Performance
87. Walford GA, Porneala BC, Dauriz M et al (2014) Metabolite traits and genetic risk provide complementary information for the prediction of future type 2 diabetes. Diabetes Care 37:2508–2514. doi:10.2337/dc14-0560
88. Wang TJ (2011) Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation 123:551–565. doi:10.1161/CIRCULATIONAHA.109.912568
89. Wang J, Stancáková A, Kuusisto J, Laakso M (2010) Identification of undiagnosed type 2 diabetic individuals by the finnish diabetes risk score and biochemical and genetic markers: a population-based study of 7232 Finnish men. J Clin Endocrinol Metab 95:3858–3862. doi:10.1210/jc.2010-0012
90. Yusuf S, Hawken S, Ounpuu S et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364:937–952. doi:10.1016/S0140-6736(04)17018-9
91. Zheng SL, Sun J, Wiklund F et al (2008) Cumulative association of five genetic variants with prostate cancer. N Engl J Med 358:910–919. doi:10.1056/NEJMoa075819